Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.47 |
| ▸ | MDM4 | O15151 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 3/20 | 0.43 |
| ▸ | PPARA | Q07869 | 6/20 | 0.42 |
| ▸ | PPARG | P37231 | 4/20 | 0.41 |
| ▸ | CASP3 | P42574 | 2/20 | 0.41 |
| ▸ | PPARD | Q03181 | 2/20 | 0.39 |
| ▸ | TLR2 | O60603 | 2/20 | 0.39 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | TDO2 | P48775 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2399667 | 1.00 | SLC17A5 (0.47) | SLC17A5MDM4TP53PPARAPPARG | |
| SCHEMBL19888241 | 0.86 | SLC17A5 (0.58) | SLC17A5MDM4TP53CASP3TLR2 | |
| SCHEMBL14063754 | 0.84 | PPARA (0.58) | SLC17A5MDM4TP53PPARAPPARG | |
| SCHEMBL8139788 | 0.83 | CASP1 (0.48) | SLC17A5MDM4TP53PPARAPPARG | |
| SCHEMBL6989365 | 0.83 | CASP1 (0.48) | SLC17A5MDM4TP53PPARAPPARG | |
| SCHEMBL24037243 | 0.82 | PPARA (0.60) | SLC17A5PPARAPPARGPPARDMDM2 | |
| SCHEMBL8541445 | 0.82 | PPARA (0.60) | SLC17A5PPARAPPARGPPARDMDM2 | |
| SCHEMBL30341699 | 0.82 | PPARA (0.60) | SLC17A5PPARAPPARGPPARDMDM2 | |
| SCHEMBL12065748 | 0.82 | PPARA (0.60) | SLC17A5PPARAPPARGPPARDMDM2 | |
| SCHEMBL12267407 | 0.80 | CYP1A2 (0.40) | SLC17A5MDM4TP53CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7919493-B2 | A compound having a fused ecteinascidin five ring system with a 1,4 bridge; anticarcinogenic agent | PHARMA MAR, S.A. (ES) | 2011-04-05 | — | — | US | disclosed |
| US-20080146580-A1 | Anititumoral Ecteinascidin Derivatives | PHARMAMAR (ES) | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146580-A1 | Anititumoral Ecteinascidin Derivatives | AREG, CD68, ASGR1 | SLC17A5 1070/4885MDM4 3411/4885TP53 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.